RET Cys634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation
Authors:
- Nuria ValdésNuria Valdés
- Elena NavarroENElena Navarro
- Jordi MesaJMJordi Mesa
- Anna CasterásACAnna Casterás
- Victoria AlcázarVAVictoria Alcázar
- Cristina LamasCristina Lamas
- Javier TébarJTJavier Tébar
- Luis CastañoLuis Castaño
- Sonia GaztambideSonia Gaztambide
- Lluís ForgaLFLluís Forga
- 1 March 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 172 (3) , 301-307
Abstract
Objective: Specific germline mutations in the RET proto-oncogene are correlated with clinical features in multiple endocrine neoplasia type 2A (MEN2A); however, data are scarce regarding differences in clinical profiles dependent on the type of nucleotide and amino acid substitution at the same codon. We aimed to analyse differences in clinical risk profiles and outcomes among different amino acids encoded by codon 634.Design: The study was retrospective and multicentric.Methods: We collected data included in the Spanish Online National Database from patients with MEN2A carrying a RET proto-oncogene mutation on codon 634. The mean follow-up time was 7.6±6.9 years (1–32).Results: Patients (n=173) from 49 unrelated families were C634Y carriers, and 26 patients from eight different families had C634R mutation. We found higher penetrance of medullary thyroid carcinoma, phaeochromocytoma and hyperparathyroidism (PP=0.007 and PPP<0.001).Conclusions: Our results suggest that there could be clinical differences caused by different amino acid substitutions at codon 634; specifically, the C634R mutation was associated with a more aggressive MEN2A phenotype than the C634Y mutation.Keywords
This publication has 19 references indexed in Scilit:
- Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An UpdateThe Journal of Clinical Endocrinology & Metabolism, 2013
- Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical managementHormones, 2009
- Familial prevalence and age of RET germline mutations: implications for screeningClinical Endocrinology, 2008
- Pheochromocytoma penetrance varies by RET mutation in MEN 2ASurgery, 2007
- RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine TumorsEndocrine Reviews, 2006
- RET Codon 634 Mutations in Multiple Endocrine Neoplasia Type 2: Variable Clinical Features and Clinical OutcomeThe Journal of Clinical Endocrinology & Metabolism, 2003
- CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2The Journal of Clinical Endocrinology & Metabolism, 2001
- Genotype-Phenotype Correlations in Hereditary Medullary Thyroid Carcinoma: Oncological Features and Biochemical PropertiesThe Journal of Clinical Endocrinology & Metabolism, 2001
- The Relationship Between Specific RET Proto-oncogene Mutations and Disease Phenotype in Multiple Endocrine Neoplasia Type 2JAMA, 1996
- Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTCNature Genetics, 1994